Beam Therapeutics Inc.
BEAM · Healthcare
$29.02
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
Beam Therapeutics announced management participation in three major investor conferences in September 2026. The company also reported progress on its BEAM-302 trial in Alpha-1 Antitrypsin Deficiency, with dosing completed for adult and adolescent patients and updated data selected for presentation at the European Respiratory Society Congress 2026.
As Sickle Cell Innovation Accelerates, Hematologists Signal Demand for a Broader Treatment Arsenal Beyond Gene Therapy
Hematologists increasingly favor a diverse sickle cell disease treatment landscape combining gene therapies with oral disease-modifying agents. Mitapivat (Agios) surged to the most desired pipeline therapy at 24% physician preference, while BEAM-101 (Beam Therapeutics) and etavopivat (Novo Nordisk) also gained traction. Despite innovation, 70% of hematologists rate unmet need as high, with 51% of SCD patients not optimally managed with current treatments.